1.
Baseline characteristics in patients with advanced ALK-positive NSCLC after occurrence of crizotinib resistance among distinct metastatic sites
| Characteristics | All (n=138) | Metastatic sites | P | ||
| Brain (n=64) | Non-liver (n=57) | Liver (n=17) | |||
| ALK, anaplastic lymphoma kinase; NSCLC, non-small-cell lung cancer; ADC, adenocarcinoma; ECOG, Eastern Cooperative Oncology Group; PS, performance status. | |||||
| Age (year) | 1.000 | ||||
| ≥60 | 31 (22.5) | 14 (21.9) | 13 (22.8) | 4 (23.5) | |
| <60 | 107 (77.5) | 50 (78.1) | 44 (77.2) | 13 (76.5) | |
| Sex | 0.939 | ||||
| Male | 63 (45.7) | 30 (46.9) | 25 (43.9) | 8 (47.1) | |
| Female | 75 (54.3) | 34 (53.1) | 32 (56.1) | 9 (52.9) | |
| Smoker history | 0.829 | ||||
| Yes | 40 (29.0) | 18 (28.1) | 16 (28.1) | 6 (35.3) | |
| No | 98 (71.0) | 46 (71.9) | 41 (71.9) | 11 (64.7) | |
| Pathologic and histological types | 0.157 | ||||
| ADC | 131 (94.9) | 63 (98.4) | 52 (91.2) | 16 (94.1) | |
| Non-ADC | 7 (5.1) | 1 (1.6) | 5 (8.8) | 1 (5.9) | |
| Clinical stage | 0.790 | ||||
| IIIB | 9 (6.5) | 5 (7.8) | 4 (7.0) | 0 (0) | |
| IV | 129 (93.5) | 59 (92.2) | 53 (93.0) | 17 (100) | |
| ECOG PS scores | 0.575 | ||||
| 0−1 | 79 (57.2) | 39 (60.9) | 32 (56.1) | 8 (47.1) | |
| ≥2 | 59 (42.8) | 25 (39.1) | 25 (43.9) | 9 (52.9) | |
| Crizotinib therapy | 0.146 | ||||
| 1 line | 74 (53.6) | 39 (60.9) | 29 (50.9) | 6 (35.3) | |
| ≥2 line | 64 (46.4) | 25 (39.1) | 28 (49.1) | 11 (64.7) | |